We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Global Commercialisation of Applied Biosystems 3500 Series Genetic Analyzers Sets New Standards for Throughput, Data Quality and Ease-of-Use
Product News

Global Commercialisation of Applied Biosystems 3500 Series Genetic Analyzers Sets New Standards for Throughput, Data Quality and Ease-of-Use

Global Commercialisation of Applied Biosystems 3500 Series Genetic Analyzers Sets New Standards for Throughput, Data Quality and Ease-of-Use
Product News

Global Commercialisation of Applied Biosystems 3500 Series Genetic Analyzers Sets New Standards for Throughput, Data Quality and Ease-of-Use


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Global Commercialisation of Applied Biosystems 3500 Series Genetic Analyzers Sets New Standards for Throughput, Data Quality and Ease-of-Use"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The 3500 Series Genetic Analyzer is for research use only not intended for therapeutic or diagnostic use.
 
Since May 2009, more than 10 research institutions have been participating in an early evaluation of the technology with primary interest in studying the most widely recognized human genetic disorders, such as those caused by extra or missing chromosomes, as well as a broad spectrum of other diseases.  Some of the global research institutions participating in the early evaluation program are the Peter MacCallum Cancer Centre, Australia; Massachusetts General Hospital, USA; Institute Paoli Calmette, France; University College London Hospital, United Kingdom; Silvestrini Hospital Molecular, Italy; Laboratório de Genômica e Biologia Molecular, Centro de Pesquisa – Hospital A. C. Camargo, Brazil; Transcriptome Research Group, National Institute of Radiological Sciences, Japan; and University of Tokyo, Japan.

The 3500 Series enables researchers to run up to 1,100 sequencing or 1,200 genotyping samples per day. It features novel consumable designs that incorporate the ability to track key information with radio frequency identification (RFID) tags, new optical and thermal systems designs, and redesigned data collection and analysis software, which enables easy generation of cost-effective analyses and high-quality data. 

Many institutions perform studies in areas such as viral/microbial typing, tissue pathology studies, cancer and other disease research, employing DNA sequencing and fragment analysis applications using CE technology.  One such example, the Diagnostic Molecular Pathology Laboratory at Massachusetts General Hospital, is currently using the 3500 system in its research studies.  Dr. John Iafrate leads the clinical service laboratory at the hospital, which conducts specialized molecular DNA oncology research.  Dr. Iafrate recently purchased a 3500 Genetic Analyzer.

Dr. Iafrate and his team are using Applied Biosystems CE technology in a variety of pre-clinical studies to investigate potential correlations between genetic mutations and the formation of disease, including cancer.  The range of research tests using CE technology include microsatellite instability analyses, sequencing, and higher-throughput genotyping of various cancer tissues to aid cancer research.

Kip Miller, President, Genetic Systems Division at Life Technologies
“The commercialisation of the Applied Biosystems 3500 Genetic Analyzer demonstrates our commitment to innovation in DNA sequencing.  We expect that highly automated and simplified solutions enabling cost-effective analyses, and repeatable high-quality data will allow researchers to broaden their   applications for this technology, and will meet our customers’ growing demand for advanced genomic analysis systems.”

Advertisement